Vertex Pharmaceuticals has announced the interim results of combination regimens of VX-770 and VX-809, two drugs to treat cystic fibrosis, from the first part of a Phase II study.

The first part of the study enrolled and randomised 62 people with two copies of the mutation in the cystic fibrosis gene, and demonstrated the safety and tolerability of the combination regimen with no serious side effects.

Peter Mueller, chief scientific officer and executive vice-president of global research and development, said that the second part of the study will begin in 2012.

The commonly reported adverse events include respiratory symptoms.